araag2/HINT huggingface dataset:
Clinical trial NCT00305604 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: sitagliptin phosphate, comparator: placebo
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Community dwelling patients 65 years of age or older diagnosed with Type 2 Diabetes
             not controlled with diet and exercise

          -  Patients must have a HbA1c of 7-10% off medication, or as a result of a protocol
             wash-out from oral anti-hyperglycemic agents by the qualifying visit

        Exclusion Criteria:

          -  Patients with type 1 diabetes

          -  History of ketoacidosis or requires insulin use

          -  Alanine aminotransferase / aspartate aminotransferase > 2.5 X ULN, triglycerides > 600
             mg/dL, creatinine clearance < 35 mL/min

          -  Fasting plasma glucose consistently > 260 mg/dL

          -  Poorly controlled hypertension
Clinical trial NCT00032890 (phase 3, status: completed)
Conditions: osteoarthritis
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: glucosamine, chondroitin sulfate, glucosamine and chondroitin sulfate combined, celecoxib
SMILES: N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O, OC(=O)CC(O)(CC(O)=O)C(O)=O, N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O, COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C
Eligibility criteria:

        40 years and above, both genders, who have clinical and radiographic osteoarthritis
        symptomatic for at least six months.
Clinical trial NCT01614457 (phase 3, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: ivacaftor, placebo
SMILES: CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female with confirmed diagnosis of CF

          -  Must have at least 1 allele of the R117H CFTR mutation

          -  Percent predicted forced expiratory volume in 1 second (FEV1) 40 percent (%) to 90%
             (for subjects aged 12 years or older) or 40% to 105% (for subjects aged 6 to 11 years)
             predicted normal for age, sex, and height

          -  6 years of age or older

          -  Minimum weight of 15 kilogram (kg) at screening

          -  Females of childbearing potential must not be pregnant

          -  Willing to comply with contraception requirements

        Exclusion Criteria:

          -  CFTR gene mutation leading to CFTR channel with gating defect (that is, any 1 of the
             following mutations: G551D, G178R, G551S, S549N, S549R, G970R, G1244E, S1251N, S1255P,
             or G1349D)

          -  History of any illness or condition that might confound the results of the study or
             pose an additional risk in administering ivacaftor to the subject

          -  An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in
             therapy (including antibiotics) for pulmonary disease within 4 weeks before the first
             dose of study drug

          -  Abnormal liver function, at screening, defined as greater than or equal to (>=) 3 time
             upper limit of normal (ULN), of any 3 or more of the following: serum aspartate
             transaminase (AST), serum alanine transaminase (ALT), gamma-glutamyl transpeptidase
             (GGT), serum alkaline phosphatase (ALP), total bilirubin

          -  Colonization with organisms associated with a more rapid decline in pulmonary status
             (for example, Burkholderia cenocepacia, Burkholderia dolosa, and Mycobacterium
             abscessus) at screening

          -  History of solid organ or hematological transplantation

          -  History of alcohol, medication or illicit drug abuse within 1 year before the first
             dose of study drug

          -  Ongoing participation in another therapeutic clinical study or prior participation in
             an investigational drug study within 30 days before screening

          -  Any "non-CF-related" illness within 2 weeks before Day 1 (first dose of study drug).
             "Illness" was defined as an acute (serious or non-serious) condition (for example,
             gastroenteritis)

          -  Use of any inhibitors or inducers of cytochrome (CYP) P450 3A
Clinical trial NCT00551382 (phase 3, status: unknown status)
Conditions: upper respiratory tract infection
ICD codes: R09.2, A15.7, A15.8, A15.9, J98.9, R06.03, J12.1
Drugs: muntelukast, placebo
SMILES: OC(=O)CC1(CC1)CS[C@H](CCC1=CC=CC=C1C(O)(C)C)C1=CC=CC(\C=C\C2=NC3=C(C=CC(Cl)=C3)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Children 1 to 5 years old without significant health problem.

        Exclusion Criteria:

          -  A previous history of wheezing (requiring treatment with bronchodilators in the last 3
             month or more than one treatment in the last year)

          -  Hospital admission due to reactive air way disease

          -  Prophylactic use of montelukast or steroids

          -  Chronic cardiac or respiratory disease

          -  Presence of acute respiratory tract infection within the 7 days before consideration
             for the study

          -  History of allergic Rhinitis

          -  Children who are receiving chronic medications of any kind

          -  Known allergy to montelukast

          -  Inability to get an informed consent from a legal guardian.
Clinical trial NCT00329472 (phase 3, status: withdrawn)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: gemcitabine, cisplatin
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Reason stopped: 
    poor enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically proven NSCLC patients

          -  All patients must have:Clinical stage IB, IIA, IIB and T3N1 by mediastinoscopy, Chest
             CT and PET-CT

          -  18 year of ages or older

          -  ECOG performance status 0-1

          -  Uni-dimensionally measurable lesion by RECIST criteria

          -  No prior chemotherapy or radiotherapy for NSCLC

          -  Pre-operative FEV1 ≥ 2.0 L evaluated within 28 days

          -  Adequate bone marrow function: Hb > 9.0 g/dL, WBC ≥ 4,000/μL, platelet count ≥
             100,000/μL

          -  Adequate liver and renal function: Total bilirubin < 2 x ULN, AST/ALT < 3 x ULN, serum
             creatinine ≤ 1.5 mg/dL, creatinine clearance ≥ 60 mL/min

          -  Written informed consent

        Exclusion Criteria:

          -  Superior sulcus tumor

          -  Prior malignancy except for adequately treated basal cell or squamous cell skin cancer
             or in situ cervical cancer at least 5 years

          -  Uncontrolled systemic illness such as DM, CHF, unstable angina or arrhythmia

          -  Recent myocardial infarction within 6 months

          -  Patients with post-obstructive pneumonia or serious infection

          -  Pregnant or nursing women (Women of reproductive potential have to agree to use an
             effective contraceptive method.)

          -  Patients with psychological problem
Clinical trial NCT00732381 (phase 3, status: completed)
Conditions: allergic rhinitis
ICD codes: J30.89, J30.9, J30.2, J30.1, J30.5, J30.81
Drugs: mometasone furoate nasal spray (mfns), matching placebo nasal spray
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  A subject must be 12 years of age or older, of either sex, and of any race.

          -  A subject must have at least a 2-year history of SAR which exacerbates during the
             study season.

          -  A subject must have a positive skin prick test response to an appropriate seasonal
             allergen at Visit 1.

          -  A subject must be clinically symptomatic at the Screening and Baseline Visits.

        Exclusion Criteria:

          -  A subject with a history of severe local reaction(s) or anaphylaxis to skin testing.

          -  A subject who has had an upper respiratory tract or sinus infection that required
             antibiotic therapy without at least a 14-day washout prior to the Screening Visit, or
             who has had a viral upper respiratory infection within 7 days prior to the Screening
             Visit.

          -  A subject who has used any drug in an investigational protocol in the 30 days prior to
             the Screening Visit.

          -  A subject who is participating in any other clinical study.

          -  A subject who is part of the staff personnel directly involved with this study.

          -  A subject who is a family member (parent, spouse, or sibling) of the investigational
             study staff.

          -  A female subject who is breast-feeding, pregnant, or intends to become pregnant.

          -  A subject previously randomized into this study.

          -  A subject who has a family member (parent, spouse, or sibling) currently enrolled in
             this study.
Clinical trial NCT01097629 (phase 3, status: completed)
Conditions: primary insomnia
ICD codes: F51.01
Drugs: suvorexant high dose (hd), suvorexant low dose (ld), comparator: placebo
SMILES: [H][C@@]1(C)CCN(CCN1C(=O)C1=C(C=CC(C)=C1)N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2, [H][C@@]1(C)CCN(CCN1C(=O)C1=C(C=CC(C)=C1)N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Must be ≥18 yrs old on the day of signing informed consent

          -  Diagnosed with Primary Insomnia

          -  Good physical and mental health

          -  Participant ≥65 yrs old score at least 25 on the Mini Mental State Examination

          -  A female participant who is of reproductive potential has a negative serum pregnancy
             test and agrees to use contraception

          -  Reports difficulty with initiating and maintaining sleep during the 4 weeks prior to
             Visit 1 (accordingly to specific protocol criteria)

          -  Reports spending 6.5 to 9 hours nightly in bed on at least 3 out of 7 nights prior to
             Visit 1

          -  Regular bedtime is between 9 pm-1 am

          -  Willing to refrain from napping while in study

          -  Able to read, understand and complete questionnaires and all diaries

          -  Willing to limit alcohol, caffeine, and nicotine consumption while in the study

          -  For a portion of participants: Must be willing to stay overnight in a sleep laboratory
             and must be willing to stay in bed for at least 8 hours each night while at the sleep
             laboratory

        Exclusion Criteria:

          -  Female participant is pregnant and/or breastfeeding at Prestudy visit, or expecting to
             conceive while in study

          -  History or diagnosis of another sleep disorder

          -  Difficulty sleeping due to a medical condition

          -  History of a neurological disorder

          -  History of bipolar disorder, psychotic disorder, or posttraumatic stress disorder, or
             current psychiatric disorder that requires a prohibited medication

          -  Ongoing depression

          -  History of substance abuse or dependence

          -  History or current evidence of a clinically significant cardiovascular disorder or
             clinically significant electrocardiogram (ECG) at Prestudy Visit

          -  Taking certain prohibited medications

          -  Consumption of the equivalent of >15 cigarettes a day

          -  History of malignancy ≤5 years prior to signing informed consent, except for
             adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer

          -  Participant is considered morbidly obese

          -  Previously randomized in another investigational study of suvorexant
Clinical trial NCT00134147 (phase 3, status: completed)
Conditions: diabetes mellitus
ICD codes: P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9
Drugs: inhaled insulin
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diabetes mellitus Type 2

          -  Failing two or more oral anti-diabetic agents

        Exclusion Criteria:

          -  Asthma, COPD

          -  Smoking
Clinical trial NCT00343252 (phase 3, status: completed)
Conditions: osteoporosis, postmenopausal, back pain, spinal fracture
ICD codes: N95.0, N95.2, M54.50, M54.51, M54.59, M84.350A, M84.454A, S92.151A, S92.151B, S92.152A, S92.152B, S92.153A
Drugs: teriparatide, risedronate, placebo, placebo
SMILES: OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Postmenopausal women 45 years or older. No period for at least two years.

          -  History of back pain that started at least 2 months prior to the initial visit (likely
             due to spinal bone fracture determined by investigator).

          -  Minimum of one moderate spinal bone fracture.

          -  Beginning pain level of at least four on an eleven point scale.

          -  Bone Mineral Density (BMD) must meet criteria

          -  Able to read, understand, and administer self-questionnaires.

          -  Be willing and able to use a pen-injector to deliver the medication.

        Exclusion Criteria:

          -  Are at increased risk for osteosarcoma.

          -  Have an active or suspected diseases that affects bone metabolism other than
             osteoporosis.

          -  Participants that already know that they will require procedures to repair their
             spinal bone fractures.

          -  Abnormal values of certain lab tests.

          -  Anything that would make it difficult to determine if the back pain was due to the
             fracture.

          -  Poor medical or psychiatric condition.

          -  Alcohol or drug abuse within a year of the study start.

          -  Certain malignant neoplasms in the 5 years prior to enrollment.

          -  Active liver disease or clinical jaundice.

          -  Significantly impaired renal function.

          -  History of nephrolithiasis or urolithiasis within 2 years prior to enrollment.

          -  Known contraindication or intolerance to risedronate and/or teriparatide therapy.

          -  Treatment with oral strontium or certain therapeutic doses of fluoride.
Clinical trial NCT00537238 (phase 3, status: completed)
Conditions: partial seizures
ICD codes: G40.111, G40.119, G40.211, G40.219, G40.101, G40.109, G40.201
Drugs: pregabalin, levetiracetam
SMILES: NCC1(CC(O)=O)CCCCC1, CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects (male or female) must be > 18 years of age, with a diagnosis of epilepsy with
             partial seizures, as defined in the International League Against Epilepsy (ILAE)
             classification of seizures.

          -  Partial seizures may be simple or complex, with or without secondary tonic-clonic
             generalization.

          -  Subjects must be have been diagnosed with epilepsy for at least 2 years, and must have
             been unresponsive to treatment with at least two but no more than five prior
             antiepileptic drugs (AEDs), and at the time of study enrollment are on stable dosages
             of 1 or 2 standard AEDs.

        Exclusion Criteria:

          -  Females who are pregnant, breastfeeding, or intend to become pregnant during the
             course of the trial will be excluded

          -  Subjects with other neurologic illness that could impair endpoint assessment, or
             subjects with Lennox-Gastaut syndrome, absence seizures, status epileptics within the
             12 months prior to trial entry, or with seizures due to an underlying medical illness
             or metabolic syndrome, will be excluded.
Clinical trial NCT00320489 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: olanzapine, olanzapine pamoate depot
SMILES: CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of schizophrenia

          -  Must be an outpatient (not requiring hospitalization) now and for at least the past 8
             weeks.

          -  Disease symptoms must meet a certain range as assessed by the clinician.

          -  Patient has experienced at least two episodes of clinical worsening of their
             condition. This could mean admission to a hospital or an emergency room visit. This
             could mean that a new medication was added, medication dose was increased, or
             medication was switched in order to better control symptoms of the condition.

          -  The patient must have an unsatisfactory response to their current medication or be
             experiencing negative effects of their current medication or not always take their
             current medication so that a change in current medication is desired.

        Exclusion Criteria:

          -  Patients who are actively suicidal.

          -  Patients who are pregnant or nursing.

          -  Patients who have stopped past treatment with olanzapine because of adverse events,
             are treatment resistant or allergic to olanzapine, or have a condition which would
             prevent use of a long acting form of olanzapine.

          -  Patients with uncorrected narrow-angle glaucoma, seizures, uncontrolled diabetes,
             certain diseases of the liver, uncontrolled thyroid condition or other serious or
             unstable illness.

          -  Patients with Parkinson's disease, psychosis related to dementia or other related
             disorders.
Clinical trial NCT00257192 (phase 3, status: terminated)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: placebo, ziprasidone oral capsules
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1
Reason stopped: 
    please see detailed description for termination reason.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria
             for schizophrenia: Current symptoms were to be present for at least 7 days before
             screening.

          -  At the Screening and Baseline visits, subjects must have had a Brief Psychiatric
             Rating Scale - Anchored score ≥35 and a score of ≥4 on at least 1 of the following
             items: unusual thought content (i.e., delusions), hallucinations, suspiciousness, or
             conceptual disorganization.

          -  Age 13 - 17 years

        Exclusion Criteria:

          -  Imminent risk of suicide or homicide, as judged by the site investigator

          -  Any history of serious or unstable medical illness, including risk for QT prolongation
Clinical trial NCT01469182 (phase 3, status: completed)
Conditions: allergy
ICD codes: T78.40XS, T78.49XS, Z91.010, Z91.012, Z91.013, Z91.030, Z91.040
Drugs: placebo for sch 39641
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical history of physician-diagnosed ragweed-induced allergic rhinoconjunctivitis
             of 2 years duration or more, with or without asthma

          -  Must have a positive skin prick test response to Ambrosia artemisiifolia

          -  Must have a forced expiratory volume in 1 second (FEV1) of at least 70% of predicted
             value

          -  Clinical laboratory tests, electrocardiogram (ECG) and vital signs conducted at the
             Screening Visit must be within normal limits or clinically acceptable to the
             investigator/sponsor

          -  Females of child-bearing potential must agree to use medically accepted methods of
             contraception

        Exclusion Criteria:

          -  Unstable asthma or has experienced an occurrence of any clinical deterioration of
             asthma that resulted in emergency treatment, hospitalization due to asthma, or
             treatment with systemic corticosteroids in previous 3 months

          -  Received an immunosuppressive treatment within 3 months

          -  History of anaphylaxis with cardio-respiratory symptoms.

          -  History of chronic urticaria or angioedema

          -  Current severe atopic dermatitis

          -  Female subject who is breastfeeding, pregnant, or intending to become pregnant

          -  Has received maintenance doses of immunotherapy with ragweed extract for ≥1 month
             within the last 5 years

          -  History of allergy, hypersensitivity or intolerance to the ingredients of the
             investigational medicinal products (IMPs) (except for Ambrosia artemisiifolia), or
             self-injectable epinephrine

          -  Unable to or will not comply with the use of self-injectable epinephrine

          -  Participating in any other clinical trial